Clinical Trial: rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia

U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07653581) titled 'rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia' on June 07.

Brief Summary: This study aims to compare the efficacy and safety of recombinant human thrombopoietin (rhTPO) + cyclosporine (CsA) and CsA monotherapy in the treatment of lower-risk myelodysplastic neoplasms with thrombocytopenia.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Lower-risk Myelodysplastic Syndromes

Intervention: DRUG: rhTPO

rhTPO 300U/kg/d, subcutaneous injection, once a month for 14 consecutive days

DRUG: Cyclosporine (CsA)

CsA 3-5mg/kg/d

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Peking Union Medical ...